Literature DB >> 27017997

Distinct Responsiveness to Intravitreal Ranibizumab Therapy in Polypoidal Choroidal Vasculopathy With Single or Multiple Polyps.

Misa Suzuki1, Norihiro Nagai1, Hajime Shinoda1, Atsuro Uchida1, Toshihide Kurihara1, Yohei Tomita1, Mamoru Kamoshita1, Chigusa Iyama1, Kazuo Tsubota1, Yoko Ozawa2.   

Abstract

PURPOSE: To understand the prognosis of polypoidal choroidal vasculopathy (PCV) by evaluating the responsiveness to intravitreal ranibizumab (IVR) monotherapy according to the presence of a single or multiple polyps.
DESIGN: Retrospective case series.
METHODS: We included 48 treatment-naïve eyes of 48 patients who received IVR monotherapy at the Medical Retina Division Clinic, Keio University Hospital between March 2009 and January 2013 and attended the clinic for at least 12 months. All patients received 3 monthly IVR injections followed by pro re nata injections and were divided into single polyp and multiple polyps groups according to indocyanine green angiography and optical coherence tomography (OCT) findings. The outcome measures included changes in best-corrected visual acuity (BCVA) and OCT findings over 2 years after initial IVR.
RESULTS: At baseline, the multiple polyps group exhibited a poorer BCVA, larger greatest linear dimension, and higher prevalence of fibrovascular pigment epithelial detachment compared with the single polyp group. Over 2 years, the multiple polyps group showed no improvement in BCVA, although the central retinal thickness (CRT) decreased in both groups. The multiple polyps group exhibited a significantly greater CRT at 1 year and required more injections in the first year compared with the single polyp group; furthermore, it included a higher number of nonresponders judged either by BCVA or fundus findings at 1 year and fundus findings at 2 years.
CONCLUSIONS: We propose that the stratification of PCV lesions according to the presence of single or multiple polyps may be valuable to understand the prognosis.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27017997     DOI: 10.1016/j.ajo.2016.03.024

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  13 in total

1.  Non-responsiveness to intravitreal aflibercept treatment in neovascular age-related macular degeneration: implications of serous pigment epithelial detachment.

Authors:  Norihiro Nagai; Misa Suzuki; Atsuro Uchida; Toshihide Kurihara; Mamoru Kamoshita; Sakiko Minami; Hajime Shinoda; Kazuo Tsubota; Yoko Ozawa
Journal:  Sci Rep       Date:  2016-07-11       Impact factor: 4.379

2.  Benefits of aflibercept treatment for age-related macular degeneration patients with good best-corrected visual acuity at baseline.

Authors:  Sakiko Minami; Norihiro Nagai; Misa Suzuki; Toshihide Kurihara; Hideki Sonobe; Mamoru Kamoshita; Atsuro Uchida; Hajime Shinoda; Hitoshi Takagi; Shozo Sonoda; Taiji Sakamoto; Kazuo Tsubota; Yoko Ozawa
Journal:  Sci Rep       Date:  2018-01-08       Impact factor: 4.379

3.  Hyperreflective Material in Optical Coherence Tomography Images of Eyes with Myopic Choroidal Neovascularization May Affect the Visual Outcome.

Authors:  Yasuaki Mushiga; Sakiko Minami; Atsuro Uchida; Norihiro Nagai; Misa Suzuki; Toshihide Kurihara; Hideki Sonobe; Norimitsu Ban; Kazuhiro Watanabe; Hajime Shinoda; Kazuo Tsubota; Yoko Ozawa
Journal:  J Clin Med       Date:  2020-07-27       Impact factor: 4.241

Review 4.  Polypoidal choroidal vasculopathy: An update on current management and review of literature.

Authors:  Amit Harishchandra Palkar; Vikas Khetan
Journal:  Taiwan J Ophthalmol       Date:  2019 Apr-Jun

5.  Association between axial length and choroidal thickness in early age-related macular degeneration.

Authors:  Maho Sato; Sakiko Minami; Norihiro Nagai; Misa Suzuki; Toshihide Kurihara; Ari Shinojima; Hideki Sonobe; Kunihiko Akino; Norimitsu Ban; Kazuhiro Watanabe; Atsuro Uchida; Hajime Shinoda; Kazuo Tsubota; Yoko Ozawa
Journal:  PLoS One       Date:  2020-10-09       Impact factor: 3.240

6.  Polypoidal Choroidal Vasculopathy.

Authors:  Joon-Bom Kim; Rajinder S Nirwan; Ajay E Kuriyan
Journal:  Curr Ophthalmol Rep       Date:  2017-04-21

7.  Clinical characteristics of super stable polypoidal choroidal vasculopathy after initial remission with anti-VEGF monotherapy.

Authors:  Seonghee Choi; Hae Min Kang; Hyoung Jun Koh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-11-27       Impact factor: 3.117

8.  Dynamic changes in choroidal conditions during anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy.

Authors:  Norihiro Nagai; Misa Suzuki; Sakiko Minami; Toshihide Kurihara; Mamoru Kamoshita; Hideki Sonobe; Kazuhiro Watanabe; Atsuro Uchida; Hajime Shinoda; Kazuo Tsubota; Yoko Ozawa
Journal:  Sci Rep       Date:  2019-08-06       Impact factor: 4.379

9.  Five-year real-world outcomes of anti-vascular endothelial growth factor monotherapy versus combination therapy for polypoidal choroidal vasculopathy in a Chinese population: a retrospective study.

Authors:  Jingyuan Yang; Mingzhen Yuan; Erqian Wang; Song Xia; Youxin Chen
Journal:  BMC Ophthalmol       Date:  2019-11-21       Impact factor: 2.209

10.  Flow signal change in polyps after anti-vascular endothelial growth factor therapy.

Authors:  Chia-Jui Chang; Yi-Ming Huang; Ming-Hung Hsieh; An-Fei Li; Shih-Jen Chen
Journal:  PLoS One       Date:  2020-10-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.